These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 20034895)

  • 1. [Effects of irbesartan on renal advanced glycation end products and their receptor in rats with early diabetic nephropathy].
    Long HB; Niu HX; Li XY; Zhou WD; He JH; Zhong J; Wei LB
    Nan Fang Yi Ke Da Xue Xue Bao; 2009 Dec; 29(12):2433-6, 2441. PubMed ID: 20034895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects of angiotensin II receptor antagonist on rat podocyte injury in early diabetic nephropathy].
    Long HB; Zhong J; Wei LB; Zhou WD; Xu ZZ
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Apr; 27(4):505-8. PubMed ID: 17545045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Extract of Ginkgo biloba and alpha-lipoic acid attenuate advanced glycation end products accumulation and RAGE expression in diabetic nephropathy rats].
    Li XZ; Yan HD; Wang J
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2011 Apr; 31(4):525-31. PubMed ID: 21608227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension.
    Busch M; Franke S; Wolf G; Rohde RD; Stein G;
    Nephron Clin Pract; 2008; 108(4):c291-7. PubMed ID: 18434751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression.
    Matsui T; Yamagishi S; Takeuchi M; Ueda S; Fukami K; Okuda S
    Pharmacol Res; 2010 Jan; 61(1):34-9. PubMed ID: 19635564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beneficial effects of metformin and irbesartan on advanced glycation end products (AGEs)-RAGE-induced proximal tubular cell injury.
    Ishibashi Y; Matsui T; Takeuchi M; Yamagishi S
    Pharmacol Res; 2012 Mar; 65(3):297-302. PubMed ID: 22100460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of irbesartan on the antioxidant defence system and nitric oxide release in diabetic rat kidney.
    Anjaneyulu M; Chopra K
    Am J Nephrol; 2004; 24(5):488-96. PubMed ID: 15353911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irbesartan ameliorates diabetic nephropathy by reducing the expression of connective tissue growth factor and alpha-smooth-muscle actin in the tubulointerstitium of diabetic rats.
    Ren X; Guan G; Liu G; Liu G
    Pharmacology; 2009; 83(2):80-7. PubMed ID: 19065061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Influence of irbesartan on renal hypertrophy and thickening of glomerular basement-membrane in streptozotocin-induced diabetic rats].
    Liu BC; Luo DD; Sun J; Ma KL; Ruan XZ
    Zhonghua Nei Ke Za Zhi; 2003 May; 42(5):320-3. PubMed ID: 12882713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression of receptor for advanced glycosylation end products and its modulation by aminoguanidine in diabetic kidney tissue.
    Huang Y; Lin S; Zhou J
    Chin Med J (Engl); 1998 Aug; 111(8):698-704. PubMed ID: 11245022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of irbesartan in prevention of renal lesion in streptozotocin-induced diabetic rats.
    Liu BC; Chen Q; Luo DD; Sun J; Phillips AO; Ruan XZ; Liu NF
    Acta Pharmacol Sin; 2003 Jan; 24(1):67-73. PubMed ID: 12511232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on streptozotocin-induced diabetic nephropathy.
    Sen S; Kanter M; Ustundag S; Aktas C; Dogutan H; Yalcin O
    Ren Fail; 2008; 30(10):1023-33. PubMed ID: 19016156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Up-regulation of glyoxalase 1 by mangiferin prevents diabetic nephropathy progression in streptozotocin-induced diabetic rats.
    Liu YW; Zhu X; Zhang L; Lu Q; Wang JY; Zhang F; Guo H; Yin JL; Yin XX
    Eur J Pharmacol; 2013 Dec; 721(1-3):355-64. PubMed ID: 24036348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The anti-inflammation effect of Moutan Cortex on advanced glycation end products-induced rat mesangial cells dysfunction and High-glucose-fat diet and streptozotocin-induced diabetic nephropathy rats.
    Zhang MH; Feng L; Zhu MM; Gu JF; Jiang J; Cheng XD; Ding SM; Wu C; Jia XB
    J Ethnopharmacol; 2014; 151(1):591-600. PubMed ID: 24269777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal expression of angiotensin receptors in long-term diabetes and the effects of angiotensin type 1 receptor blockade.
    Bonnet F; Candido R; Carey RM; Casley D; Russo LM; Osicka TM; Cooper ME; Cao Z
    J Hypertens; 2002 Aug; 20(8):1615-24. PubMed ID: 12172324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of angiotensin receptor blocker on phenotypic alterations of podocytes in early diabetic nephropathy.
    Dai HY; Zheng M; Tang RN; Ni J; Ma KL; Li Q; Liu BC
    Am J Med Sci; 2011 Mar; 341(3):207-14. PubMed ID: 21326079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal protection by low dose irbesartan in diabetic nephropathy is paralleled by a reduction of inflammation, not of endoplasmic reticulum stress.
    Hartner A; Cordasic N; Klanke B; Menendez-Castro C; Veelken R; Schmieder RE; Hilgers KF
    Biochim Biophys Acta; 2014 Apr; 1842(4):558-65. PubMed ID: 24418215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Renal protective effect of angiotensin II receptor antagonist on growth hormone-treated nephrotic rats].
    Li S; Cao B; Feng QH; Li XZ
    Zhonghua Er Ke Za Zhi; 2003 Nov; 41(11):817-21. PubMed ID: 14728886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of tripterygium wilfordii polyglucoside on expression of Activin A and influence of transdifferentiation in renal tubulointerstitium of rats with diabetic nephropathy].
    Zhao C; Yu W; Ren X; Zhang W; Li H
    Zhonghua Yi Xue Za Zhi; 2014 May; 94(18):1427-32. PubMed ID: 25142998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression.
    Ojima A; Ishibashi Y; Matsui T; Maeda S; Nishino Y; Takeuchi M; Fukami K; Yamagishi S
    Am J Pathol; 2013 Jan; 182(1):132-41. PubMed ID: 23159951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.